Blog

Latest news and articles!

Calgary, Alberta, October 4, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE:2VFO) is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial

Calgary, Alberta, September 27, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE:2VFO) is pleased to announce the appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its

Calgary, Alberta, September 20, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM, OTC: HMTXF, FSE:2VFO) is pleased to announce the appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board. Dr. Hébert

Calgary, Alberta, September 16, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF, FSE:2VFO) is pleased to announce the appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board. Dr. Giannetti

Calgary, Alberta, September 15, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce the appointment of Dr. Johannes Grillari to its Scientific Advisory Board. Since 2019, Dr. Johannes

Calgary, Alberta, September 14, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC, to its Scientific Advisory Board. Dr. Cecere

Calgary, Alberta, September 14, 2020: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) invites individuals, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging

Calgary, Alberta, September 12, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce the appointment of Mr. Thomas Abraham, CA as President, PreCerv Inc. Mr. Abraham has more

August 31, 2022, Calgary, Alberta — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE:2VF0) received numerous enquiries about the press release of August 30, 2022. This press release details the results in

August 30, 2022, Calgary, Alberta — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE:2VF0) is pleased to announce the results of its Phase II Clinical Trial and the results of a new

Other news.